



Rapid Communication

Characterising global risk profiles of Mpox clade lb importation

Toshiaki R. Asakura^(b), MD, MSc^{1,2,3}, Sung-mok Jung^(b), PhD⁴, Shihui Jin^(b), PhD⁵, Gang Hu, PhD⁵, Akira Endo^(b), MD, PhD^{1,2,3,5} and Borame Lee Dickens^(b), PhD⁵

¹Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK, ²Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK, ³School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan, ⁴Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA and ⁵Saw Swee Hock School of Public Health, National University of Singapore, 117549, Singapore

*To whom correspondence should be addressed. Email: aendo@nus.edu.sg

Submitted 8 September 2024; Revised 22 September 2024; Editorial Decision 26 September 2024; Accepted 15 October 2024

Key words Mpox, clade lb, importation risk, travel volume

In September 2023, a cluster of mpox cases were reported in the Kamituga health zone of the South Kivu province, the Democratic Republic of Congo (DRC), from which a novel virus clade Ib was identified.¹ Genetic analyses have shown evidence of sustained human-to-human transmission since its emergence,¹ with rapid spread to other health zones in South Kivu and neighbouring countries, including Burundi, Rwanda, Uganda and Kenya by August 2024. Unlike clade Ia, primarily driven by zoonotic exposure and limited human-to-human transmission typically within households,² clade Ib has been reported to be additionally spread through sexual contact, highlighted by the increased risk among sex workers and their clients.³ Although substantial uncertainty exists in whether and how clade Ib may have altered its behaviour, the observed shift in transmission modes and rapid spread has prompted the (re-)declaration of the World Health Organisation's Public Health Emergency of International Concern (PHEIC) on mpox. Shortly after, clade Ib reached beyond the African continent with two travel-associated cases reported in Sweden and Thailand on 15 and 22 August 2024, respectively.⁴

International flight travel volume data can help to infer and contextualize the country-specific risk of importing clade Ib mpox cases into countries currently without local transmission (Figure 1A). We used a simple statistical model assuming the risk of importation in a country is proportional to the OAG flight travel volume (monthly average from May 2023 to June 2024) from the source countries. Given the two importations observed outside Africa, we estimate that 23 183 (95% confidence interval: 3765-72 255) local clade Ib infections may have accumulated in the DRC, assuming the DRC is the primary


source of exportation and that no additional undetected importations exist (see Supplementary Materials for methodological details and Table S1 for a sensitivity analysis assuming additional source countries). As of August 2024, the reported numbers of confirmed and suspected cases in the North and South Kivu provinces—where clade Ib is known to circulate in the DRC are 1443 and 5077, respectively. This discrepancy may suggest moderate underreporting of clade Ib infections in the DRC.

We simulated the likely phase at which a country may experience its first clade Ib importation (Figure 1B and C) by estimating how many imported cases and countries would be recorded before the first importation occurs. This provides an overview of the clade Ib importation landscape, showing a likelihood of immediate importation in a country based on importations reported elsewhere. We obtained similar results in our sensitivity analysis where we assumed countries with confirmed cases other than the DRC are also sources of exportation (Figures S1 and S2).

Our simulations suggest that neither Sweden (36th [95% range: 3rd-74th] country to import in our simulation) nor Thailand (47th [6th-88th]), reporting the first two importations, is among the countries to expect the earliest importation. While the full travel history of these two cases, including origin, destination and stopovers, may explain this discrepancy, it also suggests potential undetected importations in countries with high travel volume. Additionally, clade Ib's deletion in the target domain could have affected PCR testing accuracy for the clade differentiation from globally circulating clade IIb,⁵ especially before the PHEIC declaration. Enhancing surveillance capacity worldwide to detect possible clade Ib arrivals is crucial to prevent

 $\textcircled{\sc c}$ International Society of Travel Medicine 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.



(C) Simulated number of countries with importations before a specific country observed one importation

Figure 1 Travel volumes and simulated number of importations and countries before the first importation in a specific country. (A) Travel volume from the DRC to international countries. (B) Simulated total number of importations before a specific country observed one importation and (C) Simulated number of countries with importations before a specific country observed one importation. Only the top 100 countries with the highest travel volume are included in the figure. Sweden and Thailand reporting an imported clade lb case are highlighted. This analysis assumes that the DRC is the only source of exportation while sensitivity analyses assuming the additional countries as sources (including Burundi, Uganda, Kenya and Rwanda) are available in the Supplementary Materials (Figures S1 and S2). Flight volumes for the above countries to Angola, Burundi, Cameroon, DRC, Central African Republic, Gabon, Kenya, Rwanda, Republic of the Congo, South Sudan, Tanzania, Uganda and Zambia were excluded as they have reported historic or current clade la or lb mpox cases.

further international spread, which would also allow the global health community to sustain support for containment in the most affected region.

Funding

T.R.A. is supported by the Rotary Foundation (GG2350294), the Nagasaki University World-leading Innovative & Smart Education (WISE) Program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for JSPS Fellows (JP24KJ1827). S-m.J. is supported by the Centers for Disease Control and Prevention Safety and Healthcare Epidemiology Prevention Research Development Programme (200-2016-91781). A.E. is supported by Japan Science and Technology Agency (JPMJPR22R3), JSPS Grantsin-Aid KAKENHI (JP22K17329) and National University of Singapore Start-Up Grant. S.J., G.H. and B.L.D. are supported by the Reimagine Research Grant, the Ministry of Education, Singapore and the Programme for Research in Epidemic Preparedness and Response (PREPARE), the Ministry of Health, Singapore.

Author contributions

T.R.A.: Conception, Investigation, Formal analysis, Writing original draft. S-m.J.: Investigation, Critical review and editing of the manuscript. S.J.: Data curation. G.H.: Data curation. A.E.: Conception, Investigation, Formal analysis, Supervision, Critical review and editing of the manuscript. B.L.D.: Investigation, Formal analysis, Supervision, Critical review and editing of the manuscript.

Conflict of interest

None declared.

Data availability

The data analysis code in the present study is deposited on https://github.com/toshiakiasakura/mpox1b_importation_risk. The OAG flight volume data was not uploaded as per the terms of the contract.

References

- Vakaniaki EH, Kacita C, Kinganda-Lusamaki E et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med 2024; 30:2791–5.
- Whitehouse ER, Bonwitt J, Hughes CM *et al.* Clinical and epidemiological findings from enhanced Monkeypox surveillance in Tshuapa province, Democratic Republic of the Congo during 2011–2015. J Infect Dis 2021; 223:1870–8.
- Masirika LM, Nieuwenhuijse DF, Ndishimye P et al. Mapping the Distribution and Describing the First Cases from an Ongoing Outbreak of a New Strain of Mpox in South Kivu, Eastern Democratic Republic of Congo between September 2023 to April 2024, medRxiv 2024. https://doi.org/10.1101/2024.05.10.24307057.
- European Centre for Disease Prevention and Control. Epidemiological update: Mpox due to monkeypox virus clade I. 2024. https://www.e cdc.europa.eu/en/news-events/epidemiological-update-mpox-duemonkeypox-virus-clade-i (6 September 2024, date last accessed).
- Masirika LM, Udahemuka JC, Schuele L *et al.* Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. *Eurosurveillance* 2024; 29:29.